What’s new

• Board approved a ₹56 cr expansion to add 11,000 MT/year of capacity at Ankleshwar, a 31% increase.
• The project will be funded entirely from internal accruals.
• The company targets completion within 12 months.

Why it matters

This is the company's largest capacity addition in recent years, using its own cash. For a firm with ₹848 crore in annual revenue, deploying 6.6% of sales on a single plant bet signals management has order visibility or firm client commitments to absorb the new volumes.

What we’re watching

• Whether the new capacity is for specific products or serves as general buffer stock.
• The plant's ramp-up timeline and initial utilization rates post-commissioning.
• How the ₹56 crore outlay affects free cash flow in FY26 and FY27.

The full read

Elantas Beck is putting ₹56 crore into its Ankleshwar plant, a bet that demand for its specialty chemicals can absorb an immediate 31% jump in capacity. The new 11,000 MT/year of output will bring the plant's total to 35,000 MT/year. Management's choice to fund the build entirely from internal accruals is the signal: for a company with ₹848 crore in annual revenue, this is a 6.6% of sales commitment made without taking on debt. The 12-month completion target is aggressive for this scale. The open question is which product segments are pulling this capacity forward, and whether the volumes are already contracted.

Primary source: BSE · NSE